Protagonist Therapeutics Inc’s filing revealed that its Officer ARTURO MOLINA acquired Company’s shares for reported $0.56 million on Jun 09 ’25. In the deal valued at $55.51 per share,10,000 shares were bought.
Then, Ali Asif sold 1,756 shares, generating $80,776 in total proceeds. Upon selling the shares at $46.00, the Chief Financial Officer now owns 61,065 shares.
Before that, Waddill William D. sold 4,000 shares. Protagonist Therapeutics Inc shares valued at $217,000 were divested by the Director at a price of $54.25 per share. As a result of the transaction, Waddill William D. now holds 13,130 shares, worth roughly $0.73 million.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Monday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock jump 2.39% to $55.68. Over the last five days, the stock has gained 11.03%. Protagonist Therapeutics Inc shares have risen nearly 44.25% since the year began. Nevertheless, the stocks have risen 63.62% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $30.67 was recorded on 02/25/25. SMA at 50 days reached $46.07, while 200 days put it at $43.72.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 54.60, which if violated will result in even more drops to 53.53. On the upside, there is a resistance level at 56.25. A further resistance level may holdings at 56.83. The Relative Strength Index (RSI) on the 14-day chart is 77.82, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.49, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 0.63%. Stochastics %K at 97.49% indicates the stock is a selling.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
